Page 31 - JCTR-11-2

Journal of Clinical and
Translational Research US-mediated drug delivery

IVIg delivered to the hippocampus with focused ultrasound 2019;132(7):802-807.
promotes neurogenesis in a model of Alzheimer’s disease. doi: 10.1016/j.amjmed.2019.03.001
Proc Natl Acad Sci U S A. 2020;117(51):32691-32700.
100. Tysnes OB, Storstein A. Epidemiology of Parkinson’s
doi: 10.1073/pnas.1908658117
disease. J Neural Transm (Vienna). 2017;124(8):901-905.
90. Antoniou A, Stavrou M, Evripidou N, et al. FUS-mediated doi: 10.1007/s00702-017-1686-y
blood-brain barrier disruption for delivering anti-Aβ
antibodies in 5XFAD Alzheimer’s disease mice. J Ultrasound. 101. Beitz JM. Parkinson’s disease: A review. Front Biosci (Schol
2024;27(2):251-262. Ed). 2014;6(1):65-74.
doi: 10.1007/s40477-023-00805-4 doi: 10.2741/s415
91. Nisbet RM, Van der Jeugd A, Leinenga G, Evans HT, 102. Reich SG, Savitt JM. Parkinson’s disease. Med Clin North
Janowicz PW, Götz J. Combined effects of scanning Am. 2019;103(2):337-350.
ultrasound and a tau-specific single chain antibody in a tau doi: 10.1016/j.mcna.2018.10.014
transgenic mouse model. Brain. 2017;140(5):1220-1230.
103. Pérez-Arancibia R, Cisternas-Olmedo M, Sepúlveda D,
doi: 10.1093/brain/awx052 Troncoso-Escudero P, Vidal RL. Small molecules to perform
92. Janowicz PW, Leinenga G, Götz J, Nisbet RM. Ultrasound- big roles: The search for Parkinson’s and Huntington’s
mediated blood-brain barrier opening enhances delivery of disease therapeutics. Front Neurosci. 2022;16:1084493.
therapeutically relevant formats of a tau-specific antibody. doi: 10.3389/fnins.2022.1084493
Sci Rep. 2019;9(1):9255.
104. Prasad EM, Hung SY. Current therapies in clinical trials
doi: 10.1038/s41598-019-45577-2
of Parkinson’s disease: A 2021 update. Pharmaceuticals
93. Bajracharya R, Cruz E, Götz J, Nisbet RM. Ultrasound- (Basel). 2021;14(8):717.
mediated delivery of novel tau-specific monoclonal antibody doi: 10.3390/ph14080717
enhances brain uptake but not therapeutic efficacy. J Control
Release. 2022;349:634-648. 105. Fan CH, Ting CY, Lin CY, et al. Noninvasive, targeted, and
non-viral ultrasound-mediated GDNF-plasmid delivery
doi: 10.1016/j.jconrel.2022.07.026 for treatment of Parkinson’s disease. Sci Rep. 2016;6:19579.
94. Mehta RI, Carpenter JS, Mehta RI, et al. Blood-brain doi: 10.1038/srep19579
barrier opening with mri-guided focused ultrasound elicits
meningeal venous permeability in humans with early 106. Yue P, Miao W, Gao L, Zhao X, Teng J. Ultrasound-triggered
Alzheimer disease. Radiology. 2021;298(3):654-662. effects of the microbubbles coupled to GDNF plasmid-
loaded PEGylated liposomes in a rat model of Parkinson’s
doi: 10.1148/radiol.2021200643
disease. Front Neurosci. 2018;12:222.
95. Rezai AR, Ranjan M, D’Haese PF, et al. Noninvasive doi: 10.3389/fnins.2018.00222
hippocampal blood-brain barrier opening in Alzheimer’s
disease with focused ultrasound. Proc Natl Acad Sci U S A. 107. Lin CY, Hsieh HY, Chen CM, et al. Non-invasive, neuron-
2020;117(17):9180-9182. specific gene therapy by focused ultrasound-induced
blood-brain barrier opening in Parkinson’s disease mouse
doi: 10.1073/pnas.2002571117
model. J Control Release. 2016;235:72-81.
96. Rezai AR, D’Haese PF, Finomore V, et al. Ultrasound blood- doi: 10.1016/j.jconrel.2016.05.052
brain barrier opening and aducanumab in Alzheimer’s
disease. N Engl J Med. 2024;390(1):55-62. 108. Zhang N, Yan F, Liang X, et al. Localized delivery of
curcumin into brain with polysorbate 80-modified
doi: 10.1056/NEJMoa2308719 cerasomes by ultrasound-targeted microbubble destruction
97. Götz J, Padmanabhan P. Ultrasound and antibodies - a for improved Parkinson’s disease therapy. Theranostics.
potentially powerful combination for Alzheimer disease 2018;8(8):2264-2277.
therapy. Nat Rev Neurol. 2024;20(5):257-258.
doi: 10.7150/thno.23734
doi: 10.1038/s41582-024-00943-1
109. Karakatsani ME, Wang S, Samiotaki G, et al. Amelioration
98. Bae S, Liu K, Pouliopoulos AN, et al. Transcranial blood- of the nigrostriatal pathway facilitated by ultrasound-
brain barrier opening in Alzheimer’s disease patients using mediated neurotrophic delivery in early Parkinson’s disease.
a portable focused ultrasound system with real-time 2-D J Control Release. 2019;303:289-301.
cavitation mapping. medRxiv [Preprint]. 2024.
doi: 10.1016/j.jconrel.2019.03.030
doi: 10.1101/2023.12.21.23300222
110. Lin CY, Lin YC, Huang CY, Wu SR, Chen CM, Liu HL.
99. Hayes MT. Parkinson’s disease and parkinsonism. Am J Med. Ultrasound-responsive neurotrophic factor-loaded

Volume 11 Issue 2 (2025) 25 doi: 10.36922/jctr.24.00061